Provided are isolated monoclonal antibodies or any antigen-binding fragment thereof which bind to hepatitis C virus E2 protein (HCV E2). In particular the presently claimed subject matter concerns neutralizing anti HCV E2 antibodies, and their use for treating HCV infection. Furthermore, the presently claimed subject matter concerns methods for preparing neutralizing anti HCV scFv antibodies associated with HCV clearance.

The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. Specifically, the disclosure provides a construct useful in expressing biotinylated antigen monomers, said construct comprising a viral protein of an ectodomain of Hepatitis C Virus (HCV) envelope glycoprotein E2 or Human Immunodeficiency Virus (HIV) gp140. Further disclosed are methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

Methods of producing and using Hepatitis C virus (HCV) eE2 polypeptides are described.

The present disclosure relates to antibodies and uses thereof for treating an HIV infection, an HCV infection, or an HIV/HCV co-infection.

The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. The present disclosure also relates to methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

The present disclosure provides monoclonal antibodies that target intracytoplasmic inclusion bodies and/or hepacivirus C NS4A and methods for their use.

The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens.

Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.

The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence compris -ing successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig′ in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig′, said intronic sequence comprising an internal 5′ splice site enabling the spli -cing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3′ terminal exon of said gene; B4) a se -quence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobulin Ig′ BCR, wherein said sequence B4) comprises, between the coding sequences of the M1 and M2 domains, an intronic sequence containing a splice site enabling the splicing of said intronic sequence between the M1 and M2 domains coding sequences; and B5) a membrane-anchored specific poly(A) signal (p AM), after the stop codon of the M2 domain, wherein the multicistronic nucleic acid enables the co-expression of the sequences A and B into separate proteins.

Provided herein are, inter alia, methods, compositions and kits for HCV antigen and vaccine design. Preferred methods include measuring neutralization of HCV pseudoparticles (HCVpp) by antibodies specific for an HCV in the biological sample, generating a neutralizations profile of each biological sample; deconvoluting the HCV-specific neutralizing antibodies by generating reference antibody neutralization profiles; correlating the reference antibody neutralization profiles to the biological sample's neutralization profile; and, identifying the HCV neutralizing antibodies.